Talent
Investor Portal
About
What We Do
FAQs
Sectors
Deep Tech
Life Sciences
Health Tech
Portfolio
Team
News
Contact
Newsroom
latest news from ose
and across our portfolio
Featured News
August 31, 2023
Oxford Science Enterprises Appoints Ed Bussey as Chief Executive Officer
Article links to www.globenewswire.com
September 27, 2023
Sitryx raises additional $39 million to progress development of disease-modifying therapeutics
Article links to prn.to
October 3, 2023
The Oxford-Harrington Rare Disease Centre Launches
Article links to www.beacontx.com
June 12, 2023
Beacon Therapeutics launches with £96 million to develop a new generation of gene therapies for retinal diseases
Article links to innovation.ox.ac.uk
May 22, 2023
Oxford University retains No. 1 spot for spinouts
Article links to www.ultromics.com
April 26, 2023
Ultromics granted FDA Breakthrough Device Designation
Article links to www.caristo.com
April 17, 2023
Caristo Diagnostics Completes Series A Financing and Welcomes New CEO
Article links to quantummotion.tech
February 21, 2023
Quantum Motion Raises £42 Million Investment Round
All News
14•12•21
Portfolio News
Circadian Therapeutics
Circadian Therapeutics announces the first subject recruited to Phase I study for CT-1500, marking move to a clinical stage company
21•07•21
Portfolio News
Circadian Therapeutics
Circadian Therapeutics and Arquimea sign a collaboration agreement for the development of a molecule (AP-2) for the treatment of diseases affecting the nervous system
Menu
About
What We Do
FAQs
Sectors
Deep Tech
Life Sciences
Health Tech
Portfolio
Team
News
Contact
Talent
Investor Portal